RBC Capital Reaffirms Their Buy Rating on Privia Health Group (PRVA)
Analyst Rating and Price Target: RBC Capital analyst Sean Dodge has maintained a Buy rating on Privia Health Group (PRVA) with a price target of $28.00, while the stock closed at $20.93. The company has a Strong Buy consensus with a price target average of $25.87.
Company Overview: Privia Health Group is a technology-driven company that partners with medical groups and health systems to enhance physician practices and patient care in both in-person and virtual settings.
Trade with 70% Backtested Accuracy
Analyst Views on PRVA
About PRVA
About the author
EHR-Enabled Colorectal Cancer Screening Achieves Significant Impact
- Screening Rate Increase: The colorectal cancer screening program led by Privia Health achieved an 84% screening rate in 2024, surpassing national benchmarks and the National Colorectal Cancer Roundtable's 80% goal, demonstrating the effectiveness of data-driven patient engagement models.
- Patient Engagement Scale: The program successfully engaged over 42,000 patients through automated outreach, with plans to expand nationally to over 100,000 patients, significantly enhancing the reach and efficiency of screenings.
- Diagnostic Follow-Up Rate: Within a 48-hour window, approximately 23,000 screening orders were processed, yielding a 10% positivity rate that identified over 550 patients requiring further diagnostic follow-up, indicating the program's potential in early cancer detection.
- Support for Value-Based Care: The initiative not only improved screening outcomes but also strengthened patient identification and documentation quality, supporting electronic clinical quality measure (eCQM) reporting and positioning health systems to meet future digital quality measurement requirements.
Privia Health Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Performance Growth: Privia Health's practice collections increased by 16.9% to $3.47 billion in 2025, while adjusted EBITDA grew by 38.8% to $125.5 million, demonstrating the company's strong execution and growth potential in the market.
- Provider Expansion: The addition of 591 new providers resulted in a year-over-year growth rate of 12.3%, bringing the total implemented providers to 5,380, with expectations to reach 5,950 by the end of 2026, further solidifying market position.
- Successful Acquisition Integration: The completion of the Evolent Health ACO business acquisition added over 120,000 value-based attributed lives, marking the company's expansion into Arizona and strengthening the foundation for future growth.
- Optimistic Cash Flow Outlook: The company projects approximately 20% growth in adjusted EBITDA for 2026, with an 80% conversion rate to free cash flow, maintaining around $600 million in cash reserves to support future business development.
Privia Health (PRVA) Q4 2025 Earnings Transcript
Privia Health Reports Q4 Earnings Beat Expectations
- Earnings Beat: Privia Health reported a Q4 non-GAAP EPS of $0.25, exceeding expectations by $0.06, indicating a robust improvement in profitability that may attract increased investor interest.
- Significant Revenue Growth: The company achieved Q4 revenue of $541 million, representing a 17.4% year-over-year increase and surpassing analyst expectations by $22.63 million, reflecting strong competitive positioning and customer demand recovery.
- Value-Based Care Model: With the introduction of CMS's new accountable care model, Privia Health is expected to benefit significantly, further expanding its value-based care services and enhancing its market position.
- Support from Historical Data: Historical financial data for Privia Health indicates stability in earnings and revenue growth, laying a solid foundation for future business development and bolstering investor confidence.
BMO Capital Begins Coverage of Privia Health Group with Outperform Rating and Sets Price Target at $30
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Evercore ISI Group Reaffirms Outperform Rating for Privia Health Group, Increases Price Target to $30
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them succeed.
Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for better trading outcomes.
Market Winning Tools: The platform is designed to equip traders with the tools and information necessary to make informed decisions in the stock market.
EHR-Enabled Colorectal Cancer Screening Achieves Significant Impact
- Screening Rate Increase: The colorectal cancer screening program led by Privia Health achieved an 84% screening rate in 2024, surpassing national benchmarks and the National Colorectal Cancer Roundtable's 80% goal, demonstrating the effectiveness of data-driven patient engagement models.
- Patient Engagement Scale: The program successfully engaged over 42,000 patients through automated outreach, with plans to expand nationally to over 100,000 patients, significantly enhancing the reach and efficiency of screenings.
- Diagnostic Follow-Up Rate: Within a 48-hour window, approximately 23,000 screening orders were processed, yielding a 10% positivity rate that identified over 550 patients requiring further diagnostic follow-up, indicating the program's potential in early cancer detection.
- Support for Value-Based Care: The initiative not only improved screening outcomes but also strengthened patient identification and documentation quality, supporting electronic clinical quality measure (eCQM) reporting and positioning health systems to meet future digital quality measurement requirements.
Privia Health Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Performance Growth: Privia Health's practice collections increased by 16.9% to $3.47 billion in 2025, while adjusted EBITDA grew by 38.8% to $125.5 million, demonstrating the company's strong execution and growth potential in the market.
- Provider Expansion: The addition of 591 new providers resulted in a year-over-year growth rate of 12.3%, bringing the total implemented providers to 5,380, with expectations to reach 5,950 by the end of 2026, further solidifying market position.
- Successful Acquisition Integration: The completion of the Evolent Health ACO business acquisition added over 120,000 value-based attributed lives, marking the company's expansion into Arizona and strengthening the foundation for future growth.
- Optimistic Cash Flow Outlook: The company projects approximately 20% growth in adjusted EBITDA for 2026, with an 80% conversion rate to free cash flow, maintaining around $600 million in cash reserves to support future business development.
Privia Health (PRVA) Q4 2025 Earnings Transcript
Privia Health Reports Q4 Earnings Beat Expectations
- Earnings Beat: Privia Health reported a Q4 non-GAAP EPS of $0.25, exceeding expectations by $0.06, indicating a robust improvement in profitability that may attract increased investor interest.
- Significant Revenue Growth: The company achieved Q4 revenue of $541 million, representing a 17.4% year-over-year increase and surpassing analyst expectations by $22.63 million, reflecting strong competitive positioning and customer demand recovery.
- Value-Based Care Model: With the introduction of CMS's new accountable care model, Privia Health is expected to benefit significantly, further expanding its value-based care services and enhancing its market position.
- Support from Historical Data: Historical financial data for Privia Health indicates stability in earnings and revenue growth, laying a solid foundation for future business development and bolstering investor confidence.
BMO Capital Begins Coverage of Privia Health Group with Outperform Rating and Sets Price Target at $30
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Evercore ISI Group Reaffirms Outperform Rating for Privia Health Group, Increases Price Target to $30
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them succeed.
Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for better trading outcomes.
Market Winning Tools: The platform is designed to equip traders with the tools and information necessary to make informed decisions in the stock market.
